The Drug Controller General of India has issued a show-cause notice to Serum Institute of India for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford Covid vaccine candidate in other countries. The Drug Controller…
Russia Approves COVID-19 Vaccine Ahead of Phase III Studies
he government of Russia has approved a vaccine for COVID-19, marking the first preventative treatment for the novel coronavirus. Despite the approval announcement, there is wide skepticism over how effective the Russian vaccine could be due to its early approval.…
The Possibility of Simultaneous COVID-19 and Flu Infections Poses a Double-Threat
As we head into cold and flu season, the question arises: Can you get COVID-19 and the flu at the same time? The short answer is: maybe. There have been some cases reported around the world of people who tested…
NanoViricides Outlines Two-Pronged Approach to Developing COVID-19 Therapies
NanoViricides, based in Shelton, Connecticut, outlined its approach to developing therapies against COVID-19 at the LD 500 investor conference yesterday. Anil R. Diwan, company president and executive chairman, indicated that since January 2020, they have been working with very limited…
Vir Bio and GSK Join the Race for a COVID-19 Monoclonal Antibody Therapy
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19. The trial is evaluating the therapy as early treatment for COVID-19 patients at high risk…
IL-6 Inhibitor Kevzara Flops in Second Phase III COVID-19 Study
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints. This marks the second such failed study for Kevzara and at least the third with IL-6 inhibitors as a potential treatment for these patients. This morning,…
How collaboration and secure data transfer is transforming clinical trials
The modern life sciences environment is increasingly focused around cloud-based work and collaboration. This requires secure, reliable and GxP-compliant data transfer software, such as that offered by Egnyte. Therapeutics, medical devices and diagnostics require effective collaboration to successfully progress from…
Why Asia-Pacific attracts 60% of all ongoing and planned hepatology trials globally
There are more than 1,300 clinical trials in hepatology, either ongoing or planned, in Asia-Pacific. This represents about 60% of all ongoing and planned hepatology trials globally. Liver diseases are highly prevalent in the Asia-Pacific region. The region hosts some…
